Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in the EU
Pfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read moreimusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read moreResearchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published in
Read moreAmerican clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read moreIn a groundbreaking development for the vaccine development sector, biotech company Valneva SE announced, that the U.S. Food and Drug
Read moreGSK plc has unveiled entering into a strategic collaboration with Chongqing Zhifei Biological Products, Ltd. (Zhifei), marking a pivotal move
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommendation is grounded in pre-clinical
Read more